An umbrella review of meta-analyses regarding the incidence of female-specific malignancies after fertility treatment

作者：Saso S, Barcroft JF, Kasaven LS, Galazis N, Ní Dhonnabháin B, Grewal KJ, Bracewell-Milnes T, Jones BP, Getreu N, Chan M, Mitra A, Al-Memar M, Ben-Nagi J, Smith JR, Yazbek J, Timmerman D, Bourne T, Ghaem-Maghami S, Verbakel JY · 发表于：Fertility and sterility · 年份：2025 · DOI：10.1016/j.fertnstert.2024.09.023 · 研究领域：Assisted reproductive technology、clomiphene citrate、female cancer、invitro fertilization、ovulation induction

IMPORTANCE: Understanding the potential risks associated with fertility treatments (FTs) can guide clinical decision and patient counseling. OBJECTIVE: To investigate the validity of the association between the development of female-specific malignancies including ovarian, endometrial, breast, and cervical cancer after FT. DATA SOURCES: A search of systematic reviews and meta-analyses was performed from inception to April 2022 within several databases: Cochrane Database of Systematic Reviews, EMBASE, Google Scholar, and PubMed. STUDY SELECTION AND SYNTHESIS: The inclusion criteria required the incidence of each cancer subgroup to be stated in both the defined treatment group (controlled ovarian stimulation and/or in vitro fertilization [IVF] or intracytoplasmic sperm injection) and the control group (no-FT, general population). From 3,129 identified publications, 11 meta-analytical reviews consisting of 188 studies were selected for synthesis. MAIN OUTCOME: The primary outcome of interest was incidence of each subgroup of cancer in the "FT" group compared with the "no-FT" group. RESULTS: A statistically significant increase in incidence of ovarian (1,229/430,611 in FT group vs. 27,358/4,263,300 in no-FT group) cancer (odds ratio [OR], 1.21; 95% confidence interval [CI], 1.00-1.45) and borderline ovarian tumors (117/414,729 in FT group vs. 934/2,626,324 in no-FT group) (OR, 1.87; 95% CI, 1.18-2.97) was observed. The incidence of ovarian cancer was higher with FT and IVF s...